---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-061848"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2023-05-17T23:59:59+00:00"
generated_at: "2026-06-14T22:30:53.730084+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharma prices $4M registered direct offering of common stock and warrants

## Summary
- Gross proceeds of ~$4M from sale of 1,333,333 shares (or pre-funded warrants) at $3.00 per share.
- Concurrent private placement of Series C and D warrants to purchase up to 2,666,666 shares at $3.26, exercisable after 6 months.
- Existing Series A and B warrants amended to extend expiry to May 18, 2029.
- Offering expected to close May 18, 2023; Maxim Group LLC as placement agent.

## SEC filing metadata
- accession: 0001104659-23-061848
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2023-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/0001104659-23-061848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/tm2315976d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-061848
- JSON: https://secwatch.observer/filing/0001104659-23-061848.json
- Plain text: https://secwatch.observer/filing/0001104659-23-061848.txt

## Key facts
- Material Agreements
  Acurx Pharmaceuticals, Inc. entered into Securities Purchase Agreement with a single healthcare-focused U.S. institutional investor named therein (the "Investor") valued at approximately $4.0 million (effective 2023-05-16).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a single healthcare-focused U.S. institutional investor named therein (the "Investor")
  - Value: approximately $4.0 million
  - Effective: 2023-05-16
  source text: On May 16, 2023, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused U.S. institutional investor named therein (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the “Registered Offering”), (i) an aggregate of 601,851 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (“Common Stock”), at an offering price of $3.00 per share and (ii) an aggregate of 731,482 pre-funded warrants exercisable for shares of Common Stock (the “Pre-Funded Warrants”) at an offering price of $2.9999 per Pre-Funded Warrant, for aggregate gross proceeds from the Registered Offering of approximately $4.0 million before deducting the placement agent fee and related offering expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/0001104659-23-061848-index.htm
- Material Agreements
  Acurx Pharmaceuticals, Inc. entered into Placement Agent Agreement with Maxim Group LLC (effective 2022-05-16).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Maxim Group LLC
  - Effective: 2022-05-16
  source text: On May 16, 2022, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with Maxim Group LLC (the “Placement Agent”) pursuant to which the Company engaged Maxim as the placement agent in connection with the Offerings.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/0001104659-23-061848-index.htm
- Material Agreements
  Acurx Pharmaceuticals, Inc. amended Warrant Amendment Agreement with the Investor.
  - Action: amendment
  - Counterparty: the Investor
  source text: In connection with the Offerings, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/0001104659-23-061848-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.